Plerixafor (AMD3100) 8HCl

Catalog No.S3013 Synonyms: JM 3100 8HCl

For research use only.

Plerixafor (AMD3100, JM 3100) 8HCl is the hydrochloride of Plerixafor, a chemokine receptor antagonist for CXCR4 and CXCL12-mediated chemotaxis with IC50 of 44 nM and 5.7 nM in cell-free assays, respectively. Plerixafor can be used as an anti-HIV agent.

Plerixafor (AMD3100) 8HCl Chemical Structure

CAS No. 155148-31-5

Selleck's Plerixafor (AMD3100) 8HCl has been cited by 35 publications

Purity & Quality Control

Choose Selective CXCR Inhibitors

Other CXCR Products

Biological Activity

Description Plerixafor (AMD3100, JM 3100) 8HCl is the hydrochloride of Plerixafor, a chemokine receptor antagonist for CXCR4 and CXCL12-mediated chemotaxis with IC50 of 44 nM and 5.7 nM in cell-free assays, respectively. Plerixafor can be used as an anti-HIV agent.
Targets
CXCL12 [1]
(Cell-free assay)
CXCR4 [1]
(Cell-free assay)
5.7 nM 44 nM
In vitro

Plerixafor inhibits CXCL12-mediated chemotaxis with a potency lightly better than its affinity for CXCR4. [1] Plerixafor also antagonizes SDF-1/CXCL12 ligand binding with an IC50 of 651 nM. Plerixafor inhibits SDF-1 mediated GTP-binding, SDF-1 mediated calcium flux and SDF-1 stimulated chemotaxis with IC50 of 27 nM, 572 nM and 51 nM, respectively. Plerixafor does not inhibit calcium flux against cells expressing CXCR3, CCR1, CCR2b, CCR4, CCR5 or CCR7 when stimulated with their cognate ligands, nor does Plerixafor inhibit receptor binding of LTB4. Plerixafor does not, on its own, induce a calcium flux in the CCRF–CEM cells, which express multiple GPCRs including CXCR4, CCR4 and CCR7. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
CHOK1 cells MV\GeY5kfGmxbjDhd5NigQ>? MYPEbZNxdGGlZX3lcpQhd2ZiW{GyOWleW0SIMXHsdIhiKG[{b32gR3hEWjRiZYjwdoV{e2WmIHnuJGNJV0tzIHPlcIx{NCCLQ{WwQVAvQDFibl2= NXviZlF6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe3NVUyOjhpPkG3O|E2OTJ6PD;hQi=>
GHOST CXCR4 cell line M3X4OWZ2dmO2aX;uJIF{e2G7 MknXTY5pcWKrdH;yfUBkd26lZX70doF1cW:wIH;mJINwdXCxdX7kJIFo[Wmwc4SgTGlXNTFiTFHJJJN1emGrbjDpckBIUE:VVDDDXGNTPCClZXzsJIxqdmVuIFnDOVA:OC57NTDuUS=> M3LONlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF2Nkm4NVg6Lz5zNE[5PFE5QTxxYU6=
HEK293 cells MWnGeY5kfGmxbjDhd5NigQ>? NGf0SlIzKGSjeYO= M2jteGFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JHQzOC2{ZYPpd5RidnRiSFnWNUBPVDRvMzDpcoZm[3SnZDDpckBJTUt{OUOgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC4aYLhcEBz\XCuaXPheIlwdiCjZoTldkAzKGSjeYOsJGlEPTB;Mj6zJI5O MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTR3MUOwOUc,OTl2NUGzNFU9N2F-
PBMC cells NYiwSYJ1TnWwY4Tpc44h[XO|YYm= MXnF[oZm[3SrdnWgZ49v[2WwdILheIlwdiCxZjDjc41xd3WwZDDh[4FqdnO2IFjJWk0yKDh7Lk[gd5Rz[WmwIHnuJHBDVUNiY3XscJMtKEWFNUC9N{45KG6P NGnkUXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNE[5PFE5QSd-MUS2PVgyQDl:L3G+
human MT4 cells MlnZSpVv[3Srb36gZZN{[Xl? NUizWYVPPCCmYYnz NU\N[JRWSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYMTCzRkBqdm[nY4Tl[EBqdiCqdX3hckBOXDRiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kB3cXK3czDy[ZBtcWOjdHnvckBi\nSncjC0JIRigXNiYomgUXRVKGG|c3H5MEBGSzVyPUSgcm0> NIfHZVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEC0N|Y{QCd-MkCwOFM3Ozh:L3G+
human Jurkat cells NIrOT2hHfW6ldHnvckBie3OjeR?= MXXBcpRi\2:waYP0JIFkfGm4aYT5JIF1KEO[Q2K0JIlvKGi3bXHuJGp2emujdDDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKFOGRkGtbY5lfWOnZDDj[YxtKG2rZ4LheIlwdixiSVO1NF0zPy52IH7N NEn1R4k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUG4PFA4OSd-MUmxPFgxPzF:L3G+
MT-4 cells Mmi4SpVv[3Srb36gZZN{[Xl? NFzmWWZG\m[nY4TpeoUh[2:wY3XueJJifGmxbjDv[kBkd22yb4Xu[EBi\2GrboP0JGhKXi1zIFnJTWIhe3S{YXnuJIlvKE2WLUSgZ4VtdHNuIFXDOVA:PjVibl2= NHvvXG09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNE[5PFE5QSd-MUS2PVgyQDl:L3G+
rat IR983F cells M2S2ZWZ2dmO2aX;uJIF{e2G7 MmXHSIl{eGyjY3Xt[Y51KG:oIGuxNlVKZUO[Q1yxNkBnem:vIFPYR3I1KGmwIILheEBKWjl6M1[gZ4VtdHNuIFnDOVA:OTB6IH7N NXftT4VRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmwOVM4PjhpPkG5NFU{PzZ6PD;hQi=>
CEM-SS cells MlvxSpVv[3Srb36gZZN{[Xl? MlPUSYZn\WO2aY\lJINwdmOnboTyZZRqd25ib3[gZ49ueG:3bnSgZYdicW6|dDDITXYuOSCOQVmgd5Rz[WmwIHnuJGNGVS2VUzDj[YxteyxiRVO1NF0yOjdibl2= NVvVd2JLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUS2PVgyQDlpPkG0Olk5OTh7PD;hQi=>
human HL60 cells M{H3WmZ2dmO2aX;uJIF{e2G7 MnT0SIl{eGyjY3Xt[Y51KG:oIGuxNlVKZVOGRkHhcJBp[SCocn;tJGNZS1J2IHnuJIh2dWGwIFjMOlAh[2WubIOsJGlEPTB;MUWuNkDPxE1? MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTF6OEC3NUc,OTlzOEiwO|E9N2F-
human MOLT4 cells M13Jc2Z2dmO2aX;uJIF{e2G7 NETTXYkyODByIH7N MXPJcohq[mm2aX;uJI9nKE2jYjCxNmc2KGKrbnTpcochfG9iQ2jDVlQh\XiycnXzd4VlKGmwIHj1cYFvKE2RTGS0JINmdGy|IHH0JFExODBibl2gZpkhTkGFUzDhcoFtgXOrcx?= MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTR3MUOwOUc,OTl2NUGzNFU9N2F-
human MT2 cells MmC0SpVv[3Srb36gZZN{[Xl? MVWxJJVoN22O MWO0JIRigXN? NX7G[2ttSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYMTCzRkBqdm[nY4Tl[EBqdiCqdX3hckBOXDJiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kB3cXKjbDDwNlQh[W62aXflckBxem:mdXP0bY9vKGG2IEGgeYcwdUxiYX\0[ZIhPCCmYYnzJIJ6KEWOSWPB NFHHTY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUG2PFM{Pid-MkGxOlg{OzZ:L3G+
human U87 cells NV;OSZFFTnWwY4Tpc44h[XO|YYm= NYe4Ro14OTByMDDuUS=> MYHBcpRi\2:waYP0JIFkfGm4aYT5JIF1KEO[Q2K0JIlvKGi3bXHuJHU5PyClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJHNFTjFvaX7keYNm\CCvb3T1cIF1cW:wIH;mJINCVVBicILv[JVkfGmxbjDheEAyODByIH7NJIJ6KFSULV\SSXQh[XO|YYm= NWHJelQyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe5OVg{PDRpPkG3PVU5OzR2PD;hQi=>
MT4 MWfBcpRqfmm{YXygZZN{[Xl? MYnBcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDITXYyKDOEIHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiCleYTvdIF1cGmlIHXm[oVkfCCrbjDNWFQh[2WubIOsJGVEPTB;MD6wNVHPxE1? MlHVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTdyM{SxNlIoRjF5MEO0NVIzRC:jPh?=
U87 M3n2VGZ2dmO2aX;uJIF{e2G7 NGTTcmYyPSCvaX7z MmrsRY51[WexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBEYEOUNDDlfJBz\XO|ZXSgbY4hcHWvYX6gWVg4KGOnbHzzJIV5eHKnc4PpcochS0R2IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiQ2jDUFEzNWmwZIXj[YQh[0GPUDDwdo9lfWO2aX;uJJBz\XS{ZXH0[YQh\m:{IEG1JI1qdnNiYnXmc5JmKG[xcoPrc4xqdiClaHHscIVv\2ViYomgWHIuTlKHVDDhcoFtgXOrczygTWM2OD1yLk[5Oe69VQ>? MnzCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFzMEW3NVUoRjJzMUC1O|E2RC:jPh?=
MT4 NYnGcYoxSW62aY\pdoFtKGG|c3H5 M1\1OmFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JHg1NXS{b4DpZ{BJUVZzIF7MOE4{KGmwZnXjeIVlKGmwIHj1cYFvKE2WNDDj[YxteyCjc4Pld5Nm\CCjczDwdo91\WO2aX;uJIZzd21idnnyeZMucW6mdXPl[EBkgXSxcHH0bI9o\W6rY3n0fUwhTUN3ME2wMlA3Os7:TR?= Mne3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ3N{m0NVgoRjJ{NUe5OFE5RC:jPh?=
MT4 Mkf6RY51cX[rcnHsJIF{e2G7 MV[1JIRigXN? NFnIU2dCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIHnu[oVkfGWmIHnuJG1VPCClZXzsd{BmgHC{ZYPzbY5oKEO[Q2K0JIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[geolzfXNvaX7keYNm\CCleYTvdIF1cGmlIHXm[oVkfCCjZoTldkA2KGSjeYOsJGVEPTB;MD6wNFLPxE1? NWTJO4Z[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK5NFkxQDhpPkKyPVA6ODh6PD;hQi=>
CHO MmTjSpVv[3Srb36gZZN{[Xl? M2roUmJqdmSrbnegZYZncW6rdImgeI8hcHWvYX6gdoVkd22kaX7hcpQhS1iFUkSg[ZhxemW|c3XkJIlvKEOKTzDj[YxteyxiS3K9NE4xPzgQvF2= MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjlyOUC4PEc,OjJ7MEmwPFg9N2F-
CHO MX7GeY5kfGmxbjDhd5NigQ>? MYTBcpRi\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJJJm[2:vYnnuZY51KEO[Q2K0JIV5eHKnc4Pl[EBqdiCFSF:gZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCVRF[xZU1qdmS3Y3XkJIVt\WO2cnnjZYwhcW2yZXThcoNmKGK7IHTp[Yxm[3S{aXOgd5Bm[3S{b4Pjc5Bq[yCjbnHsfZNqeyxiSVO1NF0xNjJ4zszN NV;zNIpRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK5NFkxQDhpPkKyPVA6ODh6PD;hQi=>
CD44null MVjGeY5kfGmxbjDhd5NigQ>? NVHEUnNyPyCmYYnz MoTFSYZn\WO2IH;uJIh2dWGwIFfCUVIh[2WubDDkbYZn\XKnboTpZZRqd25iYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hS0R2NH71cIwh[2WubIOgZYZ1\XJiNzDkZZl{KGK7IH\sc5ch[3m2b33leJJq[yCjbnHsfZNqew>? NXjhbIxbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK5NFkxQDhpPkKyPVA6ODh6PD;hQi=>
CD44null NHfjPYFHfW6ldHnvckBie3OjeR?= NVvoZ2NCPyCmYYnz Mle0SYZn\WO2IH;uJIh2dWGwIFfCUVEh[2WubDDkbYZn\XKnboTpZZRqd25iYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hS0R2NH71cIwh[2WubIOgZYZ1\XJiNzDkZZl{KGK7IH\sc5ch[3m2b33leJJq[yCjbnHsfZNqew>? M1\tU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OUC5NFg5Lz5{MkmwPVA5QDxxYU6=
Assay
Methods Test Index PMID
Immunofluorescence CXCR4 ; β-arrestin2 28521261 31186083
In vivo A single topical application of Plerixafor promotes wound healing in diabetic mice by increasing cytokine production, mobilizing bone marrow EPCs, and enhancing the activity of fibroblasts and monocytes/macrophages, thereby increasing both angiogenesis and vasculogenesis. [3] Cohorts of mice are administered with PBS, IGF1, PDGF, SCF, or VEGF for five consecutive days and Plerixafor on the 5th day. The number and size of the colonies are highest in IGF1 plus Plerixafor injected mice compared to PDGF, SCF and VEGF treated groups, in combination with Plerixafor. [4]

Protocol (from reference)

Animal Research:[4]
  • Animal Models: Twelve-week-old C57BL/6 mice with segmental bone defect
  • Dosages: 5 mg/kg
  • Administration: Administered via i.p.
  • (Only for Reference)

Solubility (25°C)

In vitro

Water 100 mg/mL
(125.87 mM)
DMSO Insoluble
Ethanol Insoluble

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing.

30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 794.47
Formula

C28H54N8.8HCl

CAS No. 155148-31-5
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C1CNCCNCCCN(CCNC1)CC2=CC=C(C=C2)CN3CCCNCCNCCCNCC3.Cl.Cl.Cl.Cl.Cl.Cl.Cl.Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04646603 Active not recruiting Drug: MRG-001|Drug: Placebo COVID-19 MedRegen LLC|ICON plc January 28 2021 Phase 1|Phase 2
NCT03547830 Recruiting Drug: Plerixafor|Drug: Gcsf Chronic Granulomatous Disease Federal Research Institute of Pediatric Hematology Oncology and Immunology April 13 2019 Phase 2
NCT03653247 Recruiting Biological: Plerixafor|Drug: Busulfan|Genetic: BIVV003 Sickle Cell Disease Bioverativ a Sanofi company|Sanofi March 6 2019 Phase 1|Phase 2
NCT03442673 Recruiting Drug: Vinorelbine|Drug: Gemcitabine|Drug: G-CSF Multiple Myeloma University Hospital Inselspital Berne September 17 2018 Phase 2

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Plerixafor (AMD3100) 8HCl | Plerixafor (AMD3100) 8HCl ic50 | Plerixafor (AMD3100) 8HCl price | Plerixafor (AMD3100) 8HCl cost | Plerixafor (AMD3100) 8HCl solubility dmso | Plerixafor (AMD3100) 8HCl purchase | Plerixafor (AMD3100) 8HCl manufacturer | Plerixafor (AMD3100) 8HCl research buy | Plerixafor (AMD3100) 8HCl order | Plerixafor (AMD3100) 8HCl mouse | Plerixafor (AMD3100) 8HCl chemical structure | Plerixafor (AMD3100) 8HCl mw | Plerixafor (AMD3100) 8HCl molecular weight | Plerixafor (AMD3100) 8HCl datasheet | Plerixafor (AMD3100) 8HCl supplier | Plerixafor (AMD3100) 8HCl in vitro | Plerixafor (AMD3100) 8HCl cell line | Plerixafor (AMD3100) 8HCl concentration | Plerixafor (AMD3100) 8HCl nmr